Aquestive Therapeutics (AQST) has received a new Buy rating, initiated by LifeSci Capital analyst, .
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
LifeScience Cap has given its Buy rating due to a combination of factors that highlight the potential of Aquestive Therapeutics. The primary value driver is Anaphylm, a sublingual film for severe allergies and anaphylaxis, which stands out as the first non-device based oral option. Its features, such as being needle-free and convenient to carry, combined with rapid efficacy, position it as a differentiated option in a growing market. The expectation of approval by the PDUFA date in January 2026 is bolstered by robust data and recent approvals of similar products.
Moreover, LifeScience Cap considers the appointment of Sherry Korczynski as Chief Commercial Officer a positive development due to her experience with EpiPen. The company’s pipeline, including Libervant for seizures and AQST-108 for alopecia areata, adds further potential value. The analyst also notes that the projected peak sales estimate for Anaphylm is conservative, suggesting significant market penetration opportunities. Overall, these factors contribute to the optimistic outlook and Buy rating for AQST.
In another report released on August 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.